KEY TAKEAWAYS
- The study aimed to evaluate the DNA methylation profiling role in meningioma and promote its widespread adoption.
- Researchers concluded that DNA methylation profiling has transformed meningioma treatment, highlighting the need for its widespread adoption to personalize care.
Over the last decade, major international research efforts have aimed at better understanding disease heterogeneity in meningioma, a type of brain cancer. Multiple molecular platforms have generated significant biological and clinical insights, highlighting the need to translate these findings into routine clinical practice.
Alexander P. Landry and the team aimed to examine the role of DNA methylation profiling in meningioma and advocate for its broader adoption.
The review explored modern DNA methylation-based classification and outcome prediction tools in meningioma. It discussed biological classifiers created without regard to outcome using unsupervised approaches, along with outcome predictors and liquid biopsy models in detail.
Results showed that DNA methylation has been effectively used for biological classification and outcome prediction in meningioma. Several groups proposed novel molecular classification systems that share similar features and outperform WHO grades in predicting outcomes and explaining subgroup-specific biological processes. Additionally, recent studies suggested a role for methylation-based liquid biopsy in meningioma, representing an exciting avenue for further exploration.
The study concluded that DNA methylation profiling has been transformative in meningioma, highlighting the need for widespread adoption to personalize care and inform clinical trial design.
No funding was declared.
Source: https://link.springer.com/article/10.1007/s11060-024-04825-w
Landry AP, Yefet LS, Wang JZ, et al. (2024). “Methylation profiling in the contemporary management of meningioma.” J Neurooncol. 2024.
https://doi.org/10.1007/s11060-024-04825-w
